E-cadherin-mediated cell-cell adhesion is frequently lost during the development of malignant epithelial cancers. Employing a transgenic mouse model of b-cell carcinogenesis (Rip1Tag2) we have previously shown that the loss of E-cadherin is a rate-limiting step in the progression from adenoma to carcinoma. However, the mere loss of cell adhesion may not be sufficient and additional signals are required to cause tumor cells to permeate the basal membrane and to invade surrounding tissue. Besides being an important component of the E-cadherin cell-adhesion complex, b-catenin plays a critical role in canonical Wnt signaling. We report here that b-catenin-mediated Wnt signaling does not contribute to tumor progression in Rip1Tag2 mice. E-cadherin downregulates b-catenin/ Tcf-mediated transcriptional activity by sequestrating b-catenin into E-cadherin cell-adhesion complexes even in the presence of activated Wnt signaling. Upon loss of E-cadherin expression, b-catenin is degraded and Tcf/ b-catenin-mediated transcriptional activity is not induced. Moreover, forced expression of constitutive-active b-catenin or genetic ablation of Tcf/b-catenin transcriptional activity in tumor cells of Rip1Tag2 transgenic mice does not affect tumor progression. Together, the data indicate that signals other than b-catenin/Tcf-mediated Wnt signaling are induced by the loss of E-cadherin during tumor progression in Rip1Tag2 transgenic mice.
Introduction
Classical cadherins are Ca 2 þ -dependent adhesion molecules that homotypically bind to adjacent cells. The best studied member of the cadherin family, E-cadherin, is distributed in the zonula adherens of epithelia and is responsible for the establishment and maintenance of a polarized cellular phenotype (reviewed by Perez-Moreno et al. (2003) ). E-cadherin connects with the actin cytoskeleton via its cytoplasmic cell-adhesion complex, a multiprotein complex consisting mainly of members of the catenin family. b-Catenin or g-catenin share a binding domain at the C-terminus of E-cadherin and link the cell adhesion plaque via a-catenin to the actin cytoskeleton. The juxtamembrane segment of E-cadherin is associated with p120 ctn . Both p120 ctn and b-catenin are substrates of tyrosine kinase (TK) receptors, such as epidermal growth factor, and allow regulation of adhesive strength by growth factor stimulation (Cavallaro and Christofori, 2004; Reynolds and Roczniak-Ferguson, 2004) .
b-Catenin and g-catenin also play an important role in canonical Wnt signaling (Nelson and Nusse, 2004; Reya and Clevers, 2005; Brembeck et al., 2006) . Free b-and g-catenin, non-sequestered by E-cadherin, are rapidly phosphorylated by glycogen synthase kinase-3b (GSK3b) in the adenomatous polyposis coli (APC)/axin/ GSK-3b/casein kinase I complex and subsequently degraded by the ubiquitin-proteasome pathway. If the tumor suppressor APC is mutated, as in several cancer types, or if GSK-3b activity is blocked by an activated Wnt pathway, b-catenin translocates to the nucleus. There, together with members of the Tcf/Lef-1 family of transcription factors, it modulates the expression of Tcf/ Lef-1-target genes implicated in cell proliferation, transformation and tumor progression, including c-Myc, cyclin D1 and D2, fibronectin, metalloproteinase (MMP)-7, Id2, axin-2 and Tcf-1 (Fodde et al., 2001; Nelson and Nusse, 2004; Reya and Clevers, 2005) . E-cadherin, by binding b-catenin and assembling an adherens junction complex, can compete with the b-catenin/Tcf-mediated transcriptional activity of the canonical Wnt-signaling pathway. Yet, such ability of E-cadherin to interfere with b-catenin-mediated Wnt signaling appears to differ between various cell types (Nelson and Nusse, 2004; Brembeck et al., 2006) . Moreover, the fact that E-cadherin does not completely deplete the cytoplasmic b-catenin pool and that it suppresses tumor cell invasion by binding b-catenin without repressing b-catenin/Tcf transcriptional activity suggests that distinct functional subsets of b-catenin may be required for cell adhesion and Wnt signaling (Gottardi and Gumbiner, 2004) .
Loss of E-cadherin function tightly correlates with tumor invasion and metastasis, and re-introduction of E-cadherin in several tumor cell lines significantly reduces their invasive potential (Behrens et al., 1989; Vleminckx et al., 1991; Christofori and Semb, 1999) . We have previously employed the Rip1Tag2 transgenic mouse model of pancreatic b-cell carcinogenesis to study the functional role of E-cadherin in tumor progression (Perl et al., 1998) . In these mice, the rat insulin gene regulatory region (Rip) is used to target expression of simian virus large T-antigen (Tag) to the b cells of the islets of Langerhans resulting in a highly reproducible multistage tumor progression pathway (Hanahan, 1985) . Forced expression of E-cadherin in tumor cells of Rip1Tag2 mice represses the formation of malignant epithelial cancers (carcinomas). Conversely, transgenic expression of a dominant-negative version of E-cadherin promotes tumor progression, with a higher incidence of carcinomas and metastases (Perl et al., 1998) . These experiments not only demonstrate a causal role for the loss of E-cadherin function in tumor progression in vivo, but also raise the possibility that the loss of E-cadherin function does not merely result in the loss of epithelial cell adhesion but may also directly activate signaling pathways that induce a migratory, invasive tumor cell phenotype.
Activation of the Wnt-signaling pathway may be one of these pathways. By its dual function b-catenin links cell-cell adhesion with Wnt signaling (Nelson and Nusse, 2004; Reya and Clevers, 2005; Brembeck et al., 2006) . Upon loss of E-cadherin function, b-catenin is released from the cytoplasmic-adhesion complex and can translocate to the nucleus, where, together with Tcf transcription factors, it contributes to Wnt signaling. Here, we have investigated the competition of E-cadherin-mediated cell-cell adhesion and Wnt signaling for b-catenin in Rip1Tag2 transgenic mice in vivo and tumor cell lines in vitro. The results indicate that, even in the presence of activated Wnt signaling, stabilized b-catenin can be sequestered by E-cadherin, thereby dominating over the Wnt pathway. Notably, neither transgenic expression of a constitutive-active b-catenin nor ablation of b-catenin/Tcf transcriptional activity by crossing Rip1Tag2 transgenic mice to Tcf-1 knockout mice affects tumor progression. Together, the results indicate that in Rip1Tag2 transgenic mice Wnt signaling is not a critical factor for tumor progression and that other, thus far unknown signaling pathways, elicited by the loss of E-cadherin, may promote tumor cell migration and invasion.
Results b-catenin relocalization upon loss of E-cadherin Previously, we have reported that the loss of E-cadherin expression is a rate-limiting event during the transition from adenoma to carcinoma in Rip1Tag2 transgenic mice (Perl et al., 1998) . Immunofluorescence analysis of E-cadherin and b-catenin expression on histological sections from Rip1Tag2 tumors revealed that E-cadherin and b-catenin colocalized to the plasma membrane of benign tumor cells (Figure 1 ). Upon loss of E-cadherin in malignant tumor cells, b-catenin relocalized to cytoplasmic compartments and declined in overall levels, as for example observed in a tumor with focal downregulation of E-cadherin expression (Figure 1) . Notably, b-catenin was not observed in nuclei of E-cadherin-negative tumor cells, also not the cells of the invasive tumor front. Also of note are the heterotypic nuclei in the invasive, E-cadherinnegative areas of the tumor (Figure 1 ).
b-Catenin is stabilized in association with E-cadherin To analyse the impact of E-cadherin on b-catenin protein levels and signaling potential we took advantage of established b-tumor cell lines derived from Rip1Tag2 tumors that completely lacked E-cadherin expression (bHC13T). These cells exhibited a highly transformed, mesenchymal phenotype, such as fibroblast-like growth pattern, foci formation and highly invasive capabilities (Supplementary Figure 1) . Forced expression of E-cadherin in bHC13T by stable transfection resulted in cobble-stone-like, epithelial monolayers with the formation of functional E-cadherin-adhesion complexes and a marked reduction of invasive phenotype (E-cad; Supplementary Figure 1) .
We next determined the fate of b-catenin in bHC13T in the presence or absence of E-cadherin and whether E-cadherin had any direct effect on b-catenin-mediated Wnt signaling. Analysis of b-catenin expression by immunoblotting revealed that its levels directly correlated with E-cadherin expression (Figure 2a) . The low amounts of b-catenin in the membrane fraction of E-cadherin-negative cells was owing to its colocalization with N-cadherin and R-cadherin, expressed at the plasma membrane of b-tumor cells (data not shown). Pulse chase experiments demonstrated that the absence of E-cadherin decreased the half-life of b-catenin protein from approximately 4 h in E-cadherin-expressing cells to less than 1 h in E-cadherin-negative cells (Figure 2b ). These results indicate that E-cadherin stabilizes high levels of b-catenin in adherens junctions at the cell membrane.
E-cadherin is dominant over Wnt signaling
To assess whether E-cadherin-mediated cell adhesion competes for b-catenin with the activated Wnt-signaling pathway, Wnt signaling was stimulated in bHC13T in the presence or absence of E-cadherin by overexpression of Wnt-1 or by stabilization of b-catenin with the proteasome inhibitor N-acetyl-Leu-Leu-Nle-CHO (ALLN) or the GSK3b inhibitor LiCl. In the presence of E-cadherin, b-catenin protein levels were high and not affected by the various stimuli of Wnt signaling, suggesting that sequestration of b-catenin to the E-cadherin-adhesion complex stabilized b-catenin protein ( Figure 3a ). In contrast, in the absence of E-cadherin, high levels of b-catenin could only be E-cadherin, b-catenin and Wnt signaling M Herzig et al detected in the presence of activated Wnt signaling. As a control, a non-degradable, constitutive-active form of b-catenin, in which the four GSK3b-phosphorylation sites at the very N-terminus were mutated (b-catenin4S), was transiently expressed and found to be stable in the absence and presence of E-cadherin ( Figure 3a) . These results indicate that b-catenin can be stabilized by both E-cadherin sequestration and activated Wnt signaling.
Whether high b-catenin levels had any effect on b-catenin/Tcf-mediated gene expression was determined by b-catenin/Tcf transcription assays with the TOP-FLASH/FOPFLASH reporter system ( Figure 3b ). E-cadherin-negative (bHC13T) and E-cadherin-expressing (E-cad) cells were transfected with either TOP-FLASH, which contains three copies of the Tcf consensus sequence coupled to a minimal TK promoter or FOPFLASH, which carries mutated Tcf sites. In addition, a Renilla luciferase reporter construct was co-transfected to normalize for transfection efficiencies. The ratio of the TOPFLASH/FOPFLASH results normalized for transfection efficiency was calculated as the relative transcriptional activity (Figure 3b ). Specific b-catenin/Tcf-mediated transcriptional activity was very low in b-tumor cells independent of E-cadherin levels. Transient expression of wild-type b-catenin modestly stimulated transcriptional activity, whereas expression of constitutive-active b-catenin 4S resulted in a dramatic increase in b-catenin/Tcf-mediated transcriptional activity in the absence of E-cadherin. In contrast, transcriptional activities were completely abrogated in the presence of E-cadherin (Figure 3b ), indicating that E-cadherin-mediated cell adhesion efficiently competed with Wnt signaling for b-catenin.
Canonical Wnt signaling does not affectRip1Tag2 tumorigenesis To investigate whether b-catenin-mediated Wnt signaling contributes to Rip1Tag2 tumor progression in vivo, we generated transgenic mouse lines expressing constitutive-active b-catenin4S under the control of the rat Figure 1 Loss of E-cadherin expression and re-localization of b-catenin during tumor progression in Rip1Tag2 transgenic mice. Immunofluorescence staining of a histological section from pancreas of a Rip1Tag2 transgenic mouse with antibodies specific for E-cadherin (green) and b-catenin (red). Note that b-catenin is colocalizing with E-cadherin at the membranes of cells in the benign portion of the tumor, whereas upon loss of E-cadherin in malignant tumor cells b-catenin is re-distributed in the tumor cells. The 4,6-diamidino-2-phenylindole staining visualizes nuclear morphology. Size bar ¼ 50 mm.
E-cadherin, b-catenin and Wnt signaling M Herzig et al insulin promoter specifically in b cells of pancreatic islets (Rip1b-catenin4S). Two independent Rip1b-catenin4S mouse lines exhibited heterogeneous expression of b-catenin4S not only at the membranes but also in the cytoplasm of b cells, at levels of transgene expression comparable to endogenous b-catenin expression (Supplementary Figure 2) . Analysis of these mouse lines did not reveal any significant effect of b-cell-specific expression of b-catenin4S on islet development and islet physiology or any signs of b-cell hyperproliferation or tumorigenesis (data not shown). Rip1b-catenin4S transgenic mice were then crossed with Rip1Tag2 mice in order to investigate the effect of activated b-catenin on b-cell tumorigenesis. Tumor volume, tumor incidence and tumor progression as measured by the ratio of adenoma to carcinoma was not changed in double-transgenic Rip1Tag2;Rip1b-catenin4S mice as compared to single-transgenic Rip1Tag2 littermate controls (Figure 4) . Moreover, tumor cell proliferation and apoptosis were also not significantly altered by the expression of b-catenin4S in tumor cells (Figure 4 ). Immunofluorescence stainings with anti-Myc antibodies to visualize Myc-tagged b-catenin4S in double-transgenic Rip1Tag2;Rip1b-catenin4S mice revealed that transgene expression was lost during tumor progression (Supplementary Figure 2) . Although in hyperplastic islets, b-catenin4S protein was still detectable in a subset of b cells, expression of the transgene was gradually lost during tumor development and was no more detectable in large adenomas and carcinomas (Supplementary Figure 2) .
Polymerase chain reaction (PCR) analysis of genomic DNA retrieved from paraffin sections of tumors revealed that, despite the lack of transgene expression, the transgene was still present in the genome of late stage tumor cells (data not shown). In contrast, northern blot analysis demonstrated that the transcript encoding the b-catenin4S transgene was absent in late stage tumors (data not shown). Immunoblotting analysis of total lysates from islets and tumors of wild-type, singletransgenic Rip1Tag2 and Rip1b-catenin4S mice and Loss of Tcf function does not affect b-cell carcinogenesis Next, we assessed whether Tcf-mediated transcriptional control contributed to Rip1Tag2 tumor progression. First, we determined expression of the four mouse homologs of Tcf, Tcf-1, Lef-1, Tcf-3 and Tcf-4, in primary Rip1Tag2 tumors and cell lines derived thereof by northern blotting and reverse transcription-PCR analysis (Supplementary Figure 4) . These experiments revealed that Tcf-1 was the only Tcf family member expressed with its two isoforms p33 and p45 in b tumor cells. Tcf-1-deficient mice have been previously reported to be viable and to display a moderate T-cell differentiation phenotype with no other pathological phenotype within the first 6 months of life (Verbeek et al., 1995) . Our close histological and physiological examination did not reveal any gross abnormalities in the development and physiology of the endocrine pancreas which is remarkable considering that Tcf-1 is the only family member expressed in pancreatic islets (data not shown).
To assess whether the loss of Tcf-1 and with it the loss of b-catenin/Tcf-mediated Wnt signaling had any effect on Rip1Tag2 tumorigenesis, we crossed Rip1Tag2 mice with Tcf-1-knockout mice. Tumor volume, tumor incidence and tumor development were found indistinguishable between wild-type and Tcf-1-deficient Rip1Tag2 mice ( Figure 5) . Furthermore, the rate of tumor cell proliferation and tumor cell apoptosis was not significantly changed by the absence or presence of Tcf-1 ( Figure 5 ). The exclusive expression of Tcf-1 in b-tumor cells was confirmed by reporter assays performed on cultured b-tumor cells, wild-type or deficient for Tcf-1 (data not shown). Although transient transfection of the TOPFLASH-reporter construct in wild-type b tumor cells resulted in significant transcriptional activity, Tcf-1-deficient b tumor cells did not exhibit any Tcf-mediated transcription (data not shown).
Immunoblotting analysis of known target genes of b-catenin/Tcf-mediated Wnt signaling in Tcf-1-expressing and Tcf-1-deficient b-tumor cells revealed that components of the E-cadherin cell-adhesion complex, including a-catenin, b-catenin, g-catenin and E-cadherin, were all expressed at comparable levels in the different genotype b-tumor cells (Figure 6 ). In contrast, expression of c-Myc and cyclin D2 was reduced in the absence of Tcf-1, whereas fibronectin, MMP-2 and osteopontin were expressed at higher levels upon loss of Tcf-1 function, indicating that Tcf-1 acted as both transcriptional repressor and activator in b-tumor cells (Figure 6 ). Yet, despite the apparent changes in gene expression in Tcf-1-deficient b-cell tumors, no significant changes in tumor growth or tumor progression were apparent. Together, these results indicate that b-catenin/ 
Discussion
Loss of E-cadherin expression is a hallmark of malignant progression of almost all epithelial cancer types. A large body of experimental data has demonstrated that the loss of E-cadherin function promotes cell migration and invasion and that maintenance of E-cadherin expression can restore epithelial morphology and prevent tumor invasion and metastasis (Thiery, 2002; Cavallaro and Christofori, 2004; Nelson and Nusse, 2004) . We have previously demonstrated that the loss of E-cadherin function indeed is a rate-limiting step during the transition from adenoma to carcinoma in Rip1Tag2 tumorigenesis (Perl et al., 1998) . Altogether these data raise the important question whether the loss of E-cadherin not only results in a loss of cell-cell adhesion but also elicits signals that actively promote cell invasion and metastasis and of what nature these signals are.
The dual role of b-catenin as cell adhesion adaptor and as Wnt-signaling effector raises the intriguing possibility that, upon loss of E-cadherin expression, b-catenin may be released from the cell-adhesion complex, translocate to the nucleus and modulate b-catenin/Tcf-mediated gene expression. Here, we have directly tested this possibility in the Rip1Tag2 mouse model of pancreatic b-cell carcinogenesis. Our results demonstrate that in cultured b-tumor cells E-cadherin quantitatively titrates b-catenin from the cytoplasmic pool, thereby competing with Wnt signaling and interfering with b-catenin/Tcf-mediated transcriptional regulation. Apparently, in b-tumor cells, E-cadherin efficiently competes with Wnt signaling for b-catenin. In contrast, E-cadherin-negative b-tumor cells exhibit only small amounts of b-catenin protein owing to its rapid degradation by the APC/GSK3b/ proteasomal degradation pathway. These results imply that the degradation machinery for b-catenin is functional in b-tumor cells of Rip1Tag2 mice and that these cells do not acquire any functional mutations in components of the Wnt-signaling cascade, as observed in a number of other cancer types.
The idea that Wnt signaling competes with cadherins for the same pool of b-catenin is originally based on experimental results during Xenopus and Drosophila embryogenesis. Cadherin overexpression mimics the wingless phenotype in Drosophila (Sanson et al., 1996) . Studies in Xenopus embryos have also shown that cadherins can inhibit Wnt signaling through recruitment of b-catenin to the plasma membrane (Heasman et al., 1994) . Similarly, E-cadherin binding prevents nuclear localization of b-catenin and b-catenin/Tcf-mediated signaling in human mammary epithelial cells overexpressing Wnt-1 and human colon carcinoma cells mutant for APC (Orsulic et al., 1999) . Comparable observations have been reported in breast, gastric and pancreatic cancer cell lines containing mutations or transcriptional silencing of the E-cadherin gene or mutations in b-or g-catenin (Caca et al., 1999; van de Wetering et al., 2001) . None of these cell lines shows activation of b-catenin-mediated Wnt signaling upon loss of E-cadherin function. These data, together with our own results, demonstrate efficient competition of E-cadherin with Wnt signaling and also imply that the consequences of APC and b-catenin mutations are distinct from the effects of E-cadherin inactivation.
In contrast to these results, a profound b-catenin/Tcfmediated transcriptional response has been reported upon loss of E-cadherin function in murine breast cancer cells (Stockinger et al., 2001) . Moreover, colon cancer cells carrying a mutation of APC exhibit increased b-catenin/Tcf-mediated transcriptional activity upon ablation of E-cadherin. These cells contain high levels of free b-catenin protein that cannot be quantitatively titrated by E-cadherin, leading to bcatenin/Tcf-mediated transcriptional activity (Gottardi et al., 2001; Gottardi and Gumbiner, 2004; Kuphal and Behrens, 2006) . These experiments also indicate the existence of functionally different pools of cytoplasmic b-catenin (Gottardi and Gumbiner, 2004) . Hence, cellular context, most likely defined by the cells' signaling status and the levels of cell adhesion and Wnt-signaling components, seems to define the outcome, that is, cell-cell adhesion or Wnt signaling.
We have also assessed whether b-catenin/Tcfmediated Wnt signaling is actually critical for the progression from benign to malignant b-cell tumors in Rip1Tag2 transgenic mice in vivo by gain and a loss of function approaches. Stimulation of Wnt signaling by the transgenic expression of a constitutive-active form of b-catenin does not affect islet development. Notably, hyperplasia or any other effect on islet cell homeostasis is not detected as a result of Wnt-signaling activation in Figure 6 Changes in the expression of Tcf-1 target genes. Wholecell protein extracts from primary b-tumor cells of wild-type or Tcf-1-deficient Rip1Tag2 mice were analysed by immunoblotting, stripping and re-probing with antibodies specific for a-, b-and g-catenin, E-cadherin, c-Myc, cyclin D2, fibronectin, MMP-2, and osteopontin and tubulin as loading control.
E-cadherin, b-catenin and Wnt signaling M Herzig et al single-transgenic Rip1b-catenin4S mice. Moreover, heterogeneous expression of activated b-catenin does not significantly affect the b-cell tumorigenesis pathway in Rip1Tag2 transgenic mice. In contrast, expression of the transgene is gradually lost during tumor progression in double-transgenic Rip1Tag2;Rip1b-catenin4S mice, suggesting that T antigen transformed b-tumor cells select against b-catenin-mediated Wnt-signaling activity. In contrast to our results, expression of an activated form of b-catenin in the skin of transgenic mice leads to hyperproliferation and benign tumors of the hair follicle (Gat et al., 1998) . Moreover, mice expressing stabilized b-catenin in the gut develop multifocal dysplastic lesions in the small intestine and colon (Harada et al., 1999; Romagnolo et al., 1999) , whereas expresssion in the liver causes liver damage in the absence of tumorigenesis (Harada et al., 2002) .
Our expression analysis reveals Tcf-1 as the only Tcf family member expressed in b-tumor cells. However, islet development is not altered in Tcf-1-deficient mice and, upon crossing with Rip1Tag2 tumor mice, b-cell tumorigenesis is not significantly affected by the loss of Tcf-1. Importantly, despite the lack of any phenotypic effect on tumor progression, expression of a number of known Wnt-signaling target genes is modulated by the absence of Tcf-1 expression. Why such alterations in the expression of genes known to play critical roles in tumorigenesis do not affect tumor progression in Rip1Tag2 mice remains unknown and certainly warrants future investigations.
From the data presented here, we conclude that signals other than Wnt signaling contribute to tumor progression upon loss of E-cadherin function in RipTag2 transgenic mice. Potential candidates are p120 ctn , which upon release from the cytoplasmic celladhesion complex can activate Rho-family GTPases and thereby modulate the actin cytoskeleton and cell migration (Reynolds and Roczniak-Ferguson, 2004) . Moreover, loss of E-cadherin frequently coincides with upregulated expression of mesenchymal cadherins, such as N-cadherin (cadherin switch), raising the possibility that not only the loss of E-cadherin but also the gain of N-cadherin function and possibly other factors may contribute to tumor progression. The activation of multiple-signaling pathways elicited by the loss of E-cadherin function is further supported by the observation that the loss of E-cadherin can induce at least parts of epithelial-mesenchymal transition concomitant with dramatic changes in gene expression programs (Thiery, 2002; Huber et al., 2005) .
Materials and methods

Transgenic mouse lines
Maintenance and phenotyping of Rip1Tag2 mice has been described previously (Hanahan, 1985) . Rip1b-catenin4S transgenic mice were generated according to standard procedures and kept in a C57Bl/6 background. Tcf-1 knockout mice were kindly provided by H Clevers, University of Utrecht, and have been described previously (Verbeek et al., 1995 
Cell culture
Tumor cell lines were established from insulinomas of 12-week-old Rip1Tag2;Tcf-1À/À and Rip1Tag2 mice as described (Herzig et al.,. 1999) . The cell line bHC13T originated from a hyperplastic cell line (bHC13; (Radvanyi et al., 1993) that had been transplanted into immunodeficient MF1 nu/nu mice and subsequently cultured from the allografted tumors. For stable transfections, bHC13T cells were transfected and selected using LipofectAMINE reagent (GIBCO, Gaithersburg, MD, USA) according to the manufacturer's recommendation. For transient transfection experiments, cells were transfected in triplicates using the FuGENE 6 Transfection Reagent (Boehringer Mannheim) according to manufacturer's protocol. TOPFLASH/FOPFLASH-constructs (kindly provided by H Clevers; (Korinek et al., 1997) and plasmids encoding for Tcf-1 or b-catenin were co-transfected together with Renilla luciferase plasmid pRL-SV40 (Promega, Wallisellen, Switzerland) to normalize for transfection efficiency. Two days after transfection luciferase activity was measured by the Luciferase reporter assay (Promega) in a Lumat LB 9507 bioluminescence counter (EG&G Berthold).
The invasive capabilities of parental bHC13T and stable transfected E-cadherin (E-cad) cell lines were determined on Biocoat Matrigel Invasion Chambers (Collaborative Biomedical Products) as described previously (Wicki et al., 2006) .
Histopathological analysis
Histology, immunohistochemistry, immunofluorescence stainings, 5-bromodeoxyuridine incorporation and TdT-mediated dNTP nick-end labeling apoptosis assays were performed as described previously (Crnic et al., 2004) . For quantification, at least 100 independent microscopic fields of tumor sections from at least 10 mice per genotype group were analysed. The following antibodies were used for immunohistochemistry and immunofluorescence: rat anti-E-cadherin (Zymed, South San Francisco, CA, USA), rabbit anti-b-catenin (Sigma, St Louis, MO, USA), mouse anti-Myc (clone9E10) (serum), guinea pig anti-insulin (DAKO, Baar, Switzerland), rabbit anti-T-antigen (serum), rat anti-CD31 (PharMingen, San Diego, CA, USA) and secondary anibodies Alexa Fluor 488/568 and biotinconjugated secondary antibodies (Amersham, Buckinghamshire, UK).
Immunoblotting Cells were lysed with RIPA buffer (150 mM NaCl, 1% NP-40, 0. 5% deoxycholate, 0.1% sodiumdodecylsulfate (SDS), 50 mM Tris-HCl pH ¼ 8.0, 10 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mM phenylmethylsulfonyl flouride) and the protein concentrations of total lysates were determined by using the Bio-Rad DC Protein Assay according to the manufacturer's specifications. Proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to nylon membranes (imobilium transfer membranes, Millipore, Billerica, MA, USA). Primary antibodies were anti-E-cadherin, anti-bcatenin, anti-a-catenin, anti-g-catenin (all Transduction Laboratory, San Jose, CA, USA), anti-tubulin (Sigma), anti-cyclinD2 (Santa Cruz, Santa Cruz, CA, USA), anti-myc (Upstate), anti-fibronectin (Sigma), anti-MMP2 (Chemicon, Dietikon, Switzerland) and anti-osteopontin (Chemicon) followed by horseradish peroxidase-conjugated anti-mouse/ rabbit antibody and visualization using the ECL chemiluminescence detection system (Amersham) according to manufacturer's recommendations.
